Document is current
Any future updates will be listed below
-
Authors
Atallah, Ehab https://orcid.org/0000-0002-9919-3564
Deininger, Michael
- License Information
-
More Information
Article History
Accepted: 7 October 2024
First Online: 6 December 2024
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Ehab Atallah: Novartis, BMS, Abbvie, and Takeda. Michael Deininger: Blueprint, Calistoqa, Cogent, CTI, DAVA Oncology, Dispersol.m Genzyme, Incyte, Novartis, Pfizer, Syneos, and Takeda.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both E.A. and M.D. wrote the paper.
